Drug class · Oncology & immunology
TNF blockers
Biologics that block tumor necrosis factor, including adalimumab, infliximab, etanercept and their biosimilars.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-187 |
| Inflectrainfliximab-dyyb | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0809 |
| Infliximab | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | Janssen Biotech, Inc. | 57894-160 |
| Remicadeinfliximab | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | Janssen Biotech, Inc. | 57894-030 |
| Renflexisinfliximab | Infliximab 100 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | Organon LLC | 78206-162 |
| Simponi Ariagolimumab | Golimumab 50 mg/4mL | SolutionIntravenous | Janssen Biotech, Inc. | 57894-350 |
| Simponigolimumab | Golimumab 50 mg/.5mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-070 |
| Simponigolimumab | Golimumab 100 mg/mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-071 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-816 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-815 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-210 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-220 |
| Zymfentrainfliximab-dyyb | Infliximab-dyyb 120 mg/mL | InjectionSubcutaneous | CELLTRION USA Inc. | 72606-047 |